Telomir Pharmaceuticals
TELO
33 hedge funds and large institutions have $3.04M invested in Telomir Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
3% more funds holding
Funds holding: 32 → 33 (+1)
0.58% less ownership
Funds ownership: 7.22% → 6.65% (-0.58%)
6% less capital invested
Capital invested by funds: $3.24M → $3.04M (-$200K)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$57.3K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.5K |
| 3 |
WIA
World Investment Advisors
Santa Barbara,
California
|
+$51.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.7K |
| 5 |
VF
Virtu Financial
New York
|
+$20.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial
St Petersburg,
Florida
|
-$105K |
| 2 |
Millennium Management
New York
|
-$80K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$71.4K |
| 4 |
Goldman Sachs
New York
|
-$31.5K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$15.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Jones Financial Companies
Des Peres,
Missouri
| $798 | – | – | – |
|
|
EWA
27
EverSource Wealth Advisors
Birmingham,
Alabama
| $504 | – | – | – |
|
28
BNP Paribas Financial Markets
Paris,
France
| $274 | -$203 | -141 | -41% |
|
29
JP Morgan Chase
New York
| $161 | +$175 | +121 | New |
|
30
Bank of America
Charlotte,
North Carolina
| $30 | – | – | – |
|
|
SS
31
SBI Securities
Tokyo,
Japan
| $5 | – | – | – |
|
32
Barclays
London,
United Kingdom
| $3 | – | – | – |
|
33
Citigroup
New York
| $1 | – | – | – |
|
|
34
Raymond James Financial
St Petersburg,
Florida
| – | -$105K | -75,340 | Closed |
|
|
35
Goldman Sachs
New York
| – | -$31.5K | -22,636 | Closed |
|
|
36
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$15.3K | -11,015 | Closed |
|
|
TRCT
37
Tower Research Capital (TRC)
New York
| – | -$1.74K | -1,251 | Closed |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -599 | Closed |
|
39
Morgan Stanley
New York
| – | -$464 | -334 | Closed |
|
|
AAP
40
Arax Advisory Partners
Denver,
Colorado
| – | -$12 | -9 | Closed |
|
TELO Hedge Fund Activity: Q4 2025 in Review
33 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q4 2025, worth a combined $3.04M — down 6.2% from $3.24M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TELO positions and 8 closed out — a net gain of 1 holder — while 3 added to existing stakes and 7 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $57.3K. The largest seller was Raymond James Financial, exiting entirely with an estimated $105K sold.
- 33 institutional investors held Telomir Pharmaceuticals (TELO) as of Q4 2025, up from 32 in Q3 2025.
- Funds reported $3.04M of Telomir Pharmaceuticals stock for Q4 2025, down 6.2% quarter-over-quarter.
- 9 funds opened new Telomir Pharmaceuticals positions in Q4 2025 and 8 closed out, a net change of +1 holder.
- The largest Telomir Pharmaceuticals buyer in Q4 2025 was XTX Topco, an estimated $57.3K added.
- The largest Telomir Pharmaceuticals seller in Q4 2025 was Raymond James Financial, an estimated $105K sold.
Based on aggregated 13F filings for Q4 2025.